AXT's InP demand surge remains a show-me story as export permits and shipment conversion stay key

What happened

The latest article highlights surging InP demand for AXT, with record InP revenues, a $100M-plus backlog, and capacity expansion, framing it as a multiyear opportunity tied to AI data-center optics. However, the master report indicates that while Q1 2026 showed a recovery with revenue of $26.9M and gross margin of 29.6%, the company still faces significant export permit hurdles, with North America revenue falling to just 2% of FY2025 sales. The $22.3M Coherent prepayment and 3-year supply agreement provide external validation, but AXT must still demonstrate that this converts into sustained shipments without inventory build or capacity misses. At a current price of $49.9, the stock already discounts a large part of the favorable future state, with an implied base case of $48 and a bear case of $30 if permits remain sporadic. Thus, the narrative of "surging demand" needs to be tempered by the operational reality that revenue is recognized shipment-by-shipment and most customer arrangements remain short-cycle purchase orders.

Implication

The stock's risk/reward is balanced at current levels, with attractive entry at $38 and trim above $65. Key checkpoints include Q2 and Q3 2026 earnings showing sequential revenue and substrate-shipment growth, and inventory not exceeding $95M without permit progress. If export permits become routine and shipments accelerate, the thesis strengthens; if not, capital is trapped in working capital and valuation could compress. Monitor Coherent's internal InP expansion, which could reduce external sourcing demand over time. Given crowdedness and recent volatility, position sizing should reflect that the story is now contract-backed but still execution-dependent.

Thesis delta

The news emphasizes record InP revenues and $100M+ backlog, which supports the demand narrative but does not alter the core execution risk. The thesis remains that AXT is attractive only after evidence shows shippable volume catching up to funded capacity and contract headlines. No change to the WAIT rating; entry at $38, trim above $65.